ArticleFrontiers in pharmacology2024
A single-dose, randomized, open-label, four-period, crossover equivalence trial comparing the clinical similarity of the proposed biosimilar rupatadine fumarate to reference Wystamm
Article in Frontiers in pharmacology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Bioequivalence Study of Two Formulations of Ibuprofen Arginine Granules in Healthy Chinese Adult Subjects.Drug design, development and therapy · 2026Trial
- Porphyrin/metalloporphyrin and their conjugates: a promising platform for drug delivery.Molecular diversity · 2026Review
- Policy-Driven Digital Health Interventions for Health Promotion and Disease Prevention: A Systematic Review of Clinical and Environmental Outcomes.Healthcare (Basel, Switzerland) · 2025Review
- Gatifloxacin detection in the nanoscale: a review exploring current biosensing technologies and future opportunities.RSC advances · 2025Review
- Personalizing cancer therapy: the role of pharmacogenetics in overcoming drug resistance and toxicity.Molecular biology reports · 2025Review
- Advanced QSPR modeling of profens using machine learning and molecular descriptors for NSAID analysis.Scientific reports · 2025Article
- A graph-based computational approach for modeling physicochemical properties in drug design.Scientific reports · 2025Article
- Innovative Formulation Strategies for Biosimilars: Trends Focused on Buffer-Free Systems, Safety, Regulatory Alignment, and Intellectual Property Challenges.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Communication Tapestry: Health Literacy Mediates Public Trust in Physician Health Information in Pakistani Public Hospitals.Healthcare (Basel, Switzerland) · 2025Article
- A Phase I Dose-Escalation Study of the Pharmacokinetics, Pharmacodynamics, and Safety of a Single Oral Dose of Tigulixostat.Drug design, development and therapy · 2025Article
- Best practices for the collection and analysis of patient experience data from social media for patient-focused drug development.Frontiers in medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The aim of this study was to evaluate the bioequivalence of two formulations of rupatadine (10-mg tablets) under fasting and fed conditions in healthy Chinese subjects. Methods: A total of 72 subjects were randomly assigned to the fasting cohort ( Results: For the fasting status, the reference-scaled average bioequivalence method was used to evaluate the bioequivalence of the maximum observed rupatadine concentration (C Conclusion: The test drug rupatadine fumarate showed a similar safety profile to the reference drug Wystamm Clinical trial registration: http://www.chinadrugtrials.org.cn/index.html, identifier CTR20213217.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.